pharmaphorum February 12, 2024
Phil Taylor

Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for rare liver disease primary biliary cholangitis (PBC), which has been filed for approval in the US.

The FDA is due to deliver a verdict on seladelpar – which was also in development for non-alcoholic steatohepatitis (NASH) before it failed a phase 3 programme – by 14th August after a priority review. It has been filed for the second-line treatment of adult PBC patients, without cirrhosis or with compensated cirrhosis, who do not respond or are intolerant to ursodeoxycholic acid (UDCA).

The $32.50-per-share offer is a 26.5% premium to CymaBay’s share price on Friday. Trading in the stock was suspended in the...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
MHE Week in Review – New PBM Reform Bill, Cardiac Diseases Cost
Deep learning uncovers gene targets and potential drugs to slow brain aging
FDA issues flu vaccine recommendations: 5 respiratory updates
CZI’s Priscilla Chan on ‘Virtual Cells’ AI Models to Cure Diseases
HIMSSCast: The 'genetic revolution' is underway

Share This Article